Aurora Spine Proposes Warrant Extension
Aurora Spine Corporation, a leading innovator in spine and interventional pain management solutions, has exciting news for its investors. The company aims to amend the terms of approximately 6,445,939 common share purchase warrants, also known as the 'Warrants'. This amendment proposal is currently pending approval from the TSX Venture Exchange. The goal is to extend the expiry date of these Warrants until October 15, 2026.
Details of the Proposed Warrant Extension
Initially, these Warrants had an exercise price set at CDN$0.50, with their original expiry date falling on October 19, 2025. They were issued as part of a recent private placement. Good news for investors: all other terms associated with these Warrants will remain unchanged throughout the extended exercise period. The enhancement in the expiry date is a strategic move that reflects Aurora Spine's commitment to fostering strong relationships with its investors.
Regulatory Considerations
The execution of this proposed Warrant extension is contingent upon acceptance by the TSX Venture Exchange. Such regulations aim to safeguard the interests of all stakeholders involved in the company. Aurora Spine Corporation emphasizes that this announcement does not signal an offer to sell or solicitation to purchase shares in the United States, as these securities will not be registered under the United States Securities Act of 1933.
About Aurora Spine Corporation
Aurora Spine is committed to redefining spinal treatment through pioneering technology. They focus on developing pioneering solutions in the spinal implant market, emphasizing minimally invasive methodologies and regenerative technologies. Their mission remains clear: to enhance surgical outcomes by prioritizing innovation, operational efficiency, and a patient-centered design approach.
Contact Information
To keep engaged in the evolving offerings of Aurora Spine, reach out to the company directly. For general inquiries:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
Website: www.aurora-spine.com
Investor Relations
For investor-related questions, you can contact:
Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com
Frequently Asked Questions
What is the purpose of the proposed Warrant extension?
The extension of the Warrants' expiry date aims to enhance investor opportunities and maintain engagement.
How many Warrants are included in the proposal?
The proposal involves a total of 6,445,939 common share purchase Warrants.
What is the new expiry date for the Warrants?
The new proposed expiry date for the Warrants is October 15, 2026.
What is the exercise price for the Warrants?
The exercise price remains set at CDN$0.50.
How can I contact Aurora Spine for more information?
You can reach out to Trent Northcutt or Chad Clouse through their provided contact details for inquiries regarding the company or its services.
